title: Renal osteodystrophy in diabetic patients.
abstract: To assess the effects of diabetes mellitus on renal osteodystrophy, we examined the database of 256 patients (45% on hemodialysis and 55% on peritoneal dialysis) who were prospectively studied in three Toronto dialysis centers between October of 1987 and 1989. All patients had serial documentation of their clinical, laboratory and risk parameters of bone disease, and completed a series of investigations that included the deferoxamine test, measurement of intact 1-84 PTH levels, and an iliac crest bone biopsy. Twenty-five percent of these patients were diabetic. When compared to non-diabetic patients, they were on dialysis for a shorter duration (2.4 +/- 0.3 vs. 4.7 +/- 0.3 years; P < 0.0002), used calcium carbonate as the only phosphate binder more frequently (40 vs. 25%; P < 0.007), and had lower parathyroid hormone levels (12 +/- 1.4 vs. 24 +/- 2.3 pmol/liter; P < 0.002). High-turnover bone disorders (that is, osteitis fibrosa and mixed disorder) were distinctly uncommon (8 vs. 33%; P < 0.01 by Fisher's exact test), while the mild (19 vs. 9%; P = NS) and the aplastic disorders (with mean stainable bone surface aluminum of 6.5 +/- 0.7%) (46 vs. 31%; P = NS) tended to be more common in diabetic patients. The prevalence of aluminum bone disease was the same in both groups (27%). Diabetic patients ingested a smaller cumulative dose of aluminum gels (3.7 +/- 0.6 vs. 9.3 +/- 1.1 kg; P < 0.005), yet had a higher rate of aluminium accumulation on bone surfaces than non-diabetic patients (1.5 +/- 0.19 vs. 0.96 +/- 0.10% per month on dialysis; P < 0.015).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Toronto Hospital, Ontario, Canada.
authors.forename: Y
authors.initials: Y
authors.lastname: Pei
authors.forename: G
authors.initials: G
authors.lastname: Hercz
authors.forename: C
authors.initials: C
authors.lastname: Greenwood
authors.forename: G
authors.initials: G
authors.lastname: Segre
authors.forename: A
authors.initials: A
authors.lastname: Manuel
authors.forename: C
authors.initials: C
authors.lastname: Saiphoo
authors.forename: S
authors.initials: S
authors.lastname: Fenton
authors.forename: D
authors.initials: D
authors.lastname: Sherrard
mesh_terms: D000368:Aged; D000535:Aluminum / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001847:Bone Diseases / Q000150:complications / Q000209:etiology / Q000473:pathology; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000150:complications* / Q000209:etiology; D003928:Diabetic Nephropathies / Q000150:complications* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D006435:Renal Dialysis / Q000009:adverse effects; D012307:Risk Factors
chemical_list: D000535:Aluminum